A manic episode is a distinct period of abnormally and persistently elevated, expansive, or irritable mood
Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, Depacon is intended for intravenous use only
Valproate was found to inhibit the metabolism of phenobarbital
WARNING: LIFE THREATENING ADVERSE REACTIONS Hepatotoxicity General Population: Hepatic failure resulting in fatalities has occurred in patients receiving valproate and its derivatives
Zarate, C
Revisions include: Patient Counseling information, and Patient Information/Patient Package Insert
24 February 2023 DEPAKOTE SPRINKLES- divalproex sodium capsule AbbVie Inc
The dose is supplied in 1 to 4 patient-specific IV infusion bag(s) in individual protective Depakote REMEDYREPACK INC
Download DRUG LABEL INFO: PDF XML Medication Guide: HTML • Depakote Sprinkle Capsules may be swallowed whole or the contents may be sprinkled on soft food
0 8
The therapeutic range is commonly considered to be 50 to 100 µg/mL of total valproate, although some patients may be controlled with lower or higher plasma concentrations
, in patients with liver disease)
slowly and with regular monitoring for fluid and nutritional intake (5
Mania: Initial dose is 25 mg/kg/day, increasing as rapidly as possible to achieve therapeutic response or desired plasma level
8
9 DRUG ABUSE AND DEPENDENCE
Obtain serum lithium concentration assay after 4 days, drawn 12 hours after the last oral dose and regularly until patient is stabilized
4) See 17 for PATIENT COUNSELING INFORMATION and Medication DRUG INTERACTIONS USE IN S HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Depakote safely and effectively
WARNING: LIFE THREATENING ADVERSE FDA Approved Labeling Text dated October 7, 2011 Page 1 of 66 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Depakote ER safely and effectively
This older group of patients should be closely monitored during treatment with Depakote ER for the development of acute liver injury with regular clinical assessments and serum liver testing
the Boxed Warning section of the package insert for Symbyax
5) • drugs metabolized by this isoenzyme (see PRECAUTIONS: Drug Interactions)
7 times the risk of death in placebo-treated patients
3) • Neuroleptic Malignant Syndrome (NMS): Manage with immediate discontinuation and close monitoring (5
6% in the placebo group
INDICATIONS AND USAGE
CAPLYTA is an atypical antipsychotic indicated for the treatment of: Schizophrenia in adults
POLG mutation screening should be performed in accordance 5
7 Pioglitazone 7
Clarithromycin is active
2
1
3 The use of this drug may impair the mental and physical abilities required for driving a car or operating heavy machinery
16 Effect on Ketone and Thyroid Function Tests 5
Dosage form: capsule, oral solution
79 • Effects on serum liver biochemistries in patients with hepatitis B or C co-infection [see Informational inserts enclosed with a drug can be cited like the example below
To break up LAMICTAL Chewable Dispersible tablets, add the tablets to a small amount of liquid (1 teaspoon, or enough to cover the medicine) in a glass or spoon
3 Dependence 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12
Drug- resistant HIV -1 variants have been identified with use of FTC/TDF for HIV-1 PrEP following undetected acute HIV-1 infection
( 2
It belongs to a class of drugs called SNRIs that work by affecting the balance of serotonin and norepinephrine in the brain
50 Infants (up to 12 months) 51 CREON should be administered to infants immediately prior to each feeding, using a dosage of 2,000 to
The active ingredient is zonisamide, 1,2 benzisoxazole-3-methanesulfonamide
6 mcg/kg/hour and titrate to achieve desired clinical effect with dosages ranging from 0
50 mg tablet: light gray, oval, film coated, tablets with "L-50" debossed on one side and "4312" on the other 100 mg tablet: light purple, oval, film coated, tablets with "L-100" debossed on one side and "4491" on the other
3826 and 7126) new depakote® er divalproex sodium extended-release tablets rx only box warning: hepatotoxicity: hepatic failure resulting in
Package insert / product label Generic name: divalproex sodium Dosage form: tablet, delayed release Drug class: Fatty acid derivative anticonvulsants
Depakote ER (AbbVie Inc
Depakote ER is intended for once-a-day oral administration
Depakote Sprinkles (AbbVie Inc
nausea or vomiting that does not go away loss of appetite pain on the right side of your stomach (abdomen) dark urine swelling of your face yellowing of your skin or the whites
WARNING: LIFE
S
1
Some valproate products are also approved to treat manic or mixed episodes associated with bipolar disorder the Boxed Warning section of the package insert for Symbyax
5) • drugs metabolized by this isoenzyme (see PRECAUTIONS: Drug Interactions)
3)]
Although the causes of death were varied, most of the deaths appeared to be either Depakote Sprinkle Capsules may be swallowed whole or the contents may be sprinkled on soft food
5%, compared to a rate of about 2
14) ADVERSE REACTIONS (5
Example: 1
Quick Links: Skip to main page Depakote ER (Divalproex Sodium) Extended-Release Tablets Company: Abbott Laboratories Application No
6 mcg/kg/hour and titrate to achieve desired clinical effect with dosages ranging from 0
3 Oral Contraceptives 7
5 Geriatric Use 5
Depakene Prescribing Information
To break up LAMICTAL Chewable Dispersible tablets, add the tablets to a small amount of liquid (1 teaspoon, or enough to cover the medicine) in a glass or spoon
Use with Anticholinergics
Nursing Mothe rs
76 The following adverse drug reactions (adverse events assessed as causally related by the 77